Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Minerva Neurosciences (NERV)

Minerva Neurosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NERV
DateTimeSourceHeadlineSymbolCompany
01/05/202412:30GlobeNewswire Inc.Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
27/02/202413:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NERVMinerva Neurosciences Inc
27/02/202413:00GlobeNewswire Inc.Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with SchizophreniaNASDAQ:NERVMinerva Neurosciences Inc
22/02/202412:00GlobeNewswire Inc.Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
22/02/202411:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NERVMinerva Neurosciences Inc
07/11/202312:30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
07/11/202312:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NERVMinerva Neurosciences Inc
05/10/202321:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
05/10/202321:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
29/09/202313:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
29/09/202313:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
28/09/202321:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NERVMinerva Neurosciences Inc
15/08/202314:28Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NERVMinerva Neurosciences Inc
15/08/202314:26Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NERVMinerva Neurosciences Inc
15/08/202314:25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NERVMinerva Neurosciences Inc
10/08/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NERVMinerva Neurosciences Inc
09/08/202322:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NERVMinerva Neurosciences Inc
04/08/202313:07Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:NERVMinerva Neurosciences Inc
01/08/202312:30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
01/08/202312:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NERVMinerva Neurosciences Inc
07/07/202321:18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NERVMinerva Neurosciences Inc
03/07/202321:04Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:NERVMinerva Neurosciences Inc
28/06/202313:38Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NERVMinerva Neurosciences Inc
28/06/202313:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NERVMinerva Neurosciences Inc
28/06/202313:30GlobeNewswire Inc.Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to MarketNASDAQ:NERVMinerva Neurosciences Inc
20/06/202313:41Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NERVMinerva Neurosciences Inc
15/05/202312:30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
15/05/202312:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NERVMinerva Neurosciences Inc
10/05/202313:00GlobeNewswire Inc.Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaNASDAQ:NERVMinerva Neurosciences Inc
08/05/202313:30GlobeNewswire Inc.Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023NASDAQ:NERVMinerva Neurosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NERV